Lancet Oncol: Prognosis reported in patients with metastatic castration-resistant prostate cancer in orapali combined with abiraterone

Prostate cancer is the second most pronatural cancer in men worldwide and the fifth leading cause

A double-blind Phase 2 trial showed that patients with metastatic, castration-resistant prostate cancer who received olapari plus abiraterone achieved significantly longer progression-free survival compared with placebo plus abiraterone

The study was a double-blind, randomized, placebo-controlled Phase 2 trial in 11 countries in Europe and South America in patients with metastatic, castration-resistant, previously treated with prostate cancer who had previously received docetaxel at least 1:1 randomized oral orolaparibal (300 mg*2 times/day) or placebo plus oral abiraterone (1000 mg/day) and oral prednisolone or prednisolone (5 mg*2 times/day) at 1:1 randomized

From 25 November 2014 to 14 July 2015, a total of 171 patients were screened, of which 29 were excluded

The average change in the least squares of BPI-SF, single most severe bone pain, and FACT-P TOI remained stable

In summary, in this exploratory analysis, when olapalli was used in combination with abiraterone, there was no significant effect on

Original source:

Fred Saad, et al.